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The function of the secretory core gene product (HBeAg) of the human hepatitis B virus is unclear. It has been discussed
that this protein may be passed from the mother to the fetus, where it might induce immunologic tolerance. Here we have
examined this possibility with transgenic mice expressing high levels of HBeAg. Analysis of serum samples obtained from
nontrangenic fetuses which developed in HBeAg-positive mothers showed no evidence that the HBeAg can pass the
placenta. Moreover, direct examination of the HBeAg- and HBcAg-specific cytotoxic T-cell immune response of H-2b mice
which developed in either transgenic or nontransgenic mothers revealed no indication that mice which could have been
exposed to the HBeAg in utero become tolerant to HBV core gene products. From these data we conclude that the placenta
represents an efficient barrier for HBeAg transfer and that the HBeAg does not tolerize cytotoxic T cells, at least in mice of
the H-2b haplotype. © 1998 Academic Press
INTRODUCTION
One of the most important features of the hepadnavi-
ruses is that they can cause chronic infections. For the
human hepatitis B virus (HBV) it is well documented that
the rate of chronicity correlates with age at the time point
of infection. Whereas babies almost invariably become
chronic virus carriers, only a small fraction of the infec-
tions of adults enter a chronic course. Since immuno-
suppression also promotes the development of chronic
infections, it appears conceivable that the reactivity of
the immune system is of major importance. Whether
certain viral gene products can directly induce tolerance
or whether the insufficient immune response is due to
other factors is a matter of debate.
One viral protein which has been suspected to act as
a tolerogen for a long time is the hepatitis B virus e
antigen (HBeAg). It is now well established that the
HBeAg represents an independent protein product
which is encoded by the HBV core gene (Ganem and
Varmus, 1987; Garcia et al., 1988; Junker et al., 1987; Ou
et al., 1986; Schlicht et al., 1987). The major protein
product encoded by this gene is the core protein or
HBcAg which is the building block of the nucleocapsid. It
is translated from the so-called pregenomic RNA whose
transcriptional start site is located within a small open
reading frame, the preC region, which precedes the core
gene. However, core gene transcription can also initiate
upstream from the preC region, which results in the
synthesis of a second mRNA designated precore mRNA.
The precore mRNA encodes a slightly longer protein
which is commonly referred to as the precore protein.
Since the 29-amino-acid-long peptide encoded by the
preC region acts as a signal sequence for secretion, the
precore protein is translocated into the lumen of the
endoplasmic reticulum (Ou et al., 1986). By N- and C-
terminal proteolytic cleavage the precore protein is con-
verted into the mature HBeAg, which is actively secreted
by HBV-infected cells. All of the hepadnaviruses exam-
ined to date encode such a secretory core gene product.
Although the biochemical pathway by which HBeAg is
produced has now been known for many years, the
function of this protein is still enigmatic. Experiments
with mutants which were first carried out with the duck
hepatitis B virus showed that production of a secretory
core gene product is not essential for the establishment
of viral infection (Chang et al., 1987; Schlicht et al., 1987).
This finding was later extended to the woodchuck and
the human hepatitis B virus (Chen et al., 1992; Ogata et
al., 1993). Since natural HBeAg-negative HBV mutants
are rather rare and mostly appear to be selected only
after many years of chronic infection, it appears possible
that the HBeAg might be important for the establishment
and maintenance of chronic infections. In a recent report
it was suggested that the HBeAg may shift the immune
response of chronic HBV carriers to a Th2-like phenotype
(Milich et al., 1997). This hypothesis is supported by the
clinical observation that the emergence of HBeAg-neg-
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ative HBV mutants during a chronic active HBV infection
is frequently associated with an exacerbation of liver
injury (Brunetto et al., 1991). Another potential mecha-
nism of HBeAg-mediated immunomodulation has been
described much earlier (Milich et al., 1990). In this report
it was suggested that the transplacental passage of
HBeAg from the maternal into the fetal circulation would
induce a partial tolerization of the fetus to HBV proteins.
This hypothesis is mainly based on the finding that in
one experiment the nontransgenic offspring of HBeAg
expressing transgenic mice which could have been ex-
posed to the HBeAg in utero were shown to possess a
lower reactivity to HBV core gene products at the helper
T-cell level compared to normal control mice. To date,
however, there is no direct evidence that HBeAg can in
fact cross the placenta and it has not been investigated
whether a potential exposure to the HBeAg in utero
could result in an impaired CTL immune response.
Recently, we described several transgenic mouse lin-
eages expressing the HBeAg at a level comparable to
that of chronically infected humans (Reifenberg et al.,
1997). We also succeeded in inducing specific cytotoxic
T-cells in mice of the H-2b haplotype by immunization
with HBc/eAg encoding plasmids. With this system we
could map an H-2b-restricted CTL epitope shared by the
two core gene products (Kuhrober et al., 1996). We now
have used these tools to analyze whether the HBeAg can
tolerize H-2b-restricted HBc/eAg-specific CTLs in utero.
Mice are well suited for examining this issue since they
have the same placentation type (placenta hemochoria-
lis) as man. We found no evidence that the HBeAg can
cross the placenta and also observed no tolerization of
H-2b-restricted cytotoxic T-cells in nontransgenic mice
born to HBeAg-positive mothers.
RESULTS
The placenta represents an efficient barrier
for HBeAg transfer
Recently we described the generation of transgenic
mice (designated cex) which, after introduction of the
HBV preC/C gene, expressed high amounts of HBeAg in
the serum (Reifenberg et al., 1997). Juvenile cex mice of
lineages cex-L and cex-C backcrossed to a C57BL/6J
(B6) background exhibited mean HBeAg titers of 56 and
43 ng HBeAg/ml, respectively. This is well within the
range which is usually observed in chronically infected
humans.
To test whether the HBeAg levels are affected by
pregnancy, pregnant B6xBALB/c-cex-L mice were sacri-
ficed on days 7, 14, and 18 postconception. Within this
period of time the HBeAg levels varied no more than
about 20% (data not shown). This shows that pregnancy
had no suppressive effect on HBeAg expression in mice
and that the fetuses therefore can potentially be exposed
to this protein during all stages of development.
To investigate whether the HBeAg can pass the pla-
centa barrier, we sacrificed pregnant cex transgenic
mothers at day 1 before delivery and prepared the fe-
tuses. Since the mothers were hemizygous for the trans-
gene, we expected 50% of the fetuses to be either trans-
genic or nontransgenic. To test this, PCR was performed
with fetal liver DNA. As is shown in Table 1, of the 36
fetuses prepared from five pregnant animals 17 were
transgenic and 19 were nontransgenic. The HBeAg in the
maternal and the fetal sera was quantitated using the
calibrated diagnostic test described. The results are also
summarized in Table 1. The mothers expressed the trans-
gene very well, as is demonstrated by serum HBeAg
titers between 34 and 107 ng/ml. However, only in 4
fetuses, which were all transgenic, small amounts of
HBeAg could be detected. All other fetuses were HBeAg
negative. In this context it is important to mention that in
both transgenic lineages used here (cex-L and cex-C)
the preC/C gene is subject to genomic imprinting. The
transgene is expressed efficiently if passed paternally,
whereas maternal inheritance results in a complete or
almost complete inactivation of gene expression (unpub-
lished data).
Since, in case of the fetal sera, the lower detection
limit of our assay was 0.5 ng HBeAg/ml (the samples had
to be diluted fivefold before analysis) and the mothers
had HBeAg titers between 34 and 107 ng/ml, the murine
placenta can maintain a HBeAg gradient of at least 100
to 200. Consequently, the placenta represents an effi-
cient barrier for HBeAg transfer. However, our analyses
could not exclude the possibility that very small amounts
TABLE 1
The Murine Placenta Represents an Efficient Barrier
for the e Protein
Mother A
(107)
Mother B
(99)
Mother C
(57)
Mother D
(48)
Mother E
(34)
A1 (0) B1 (0) C1 (0) D1 (0) E1 (0)
A2 (0) B2 (0) C2 (0.7) D2 (0) E2 (0)
A3 (0) B3 (0) C3 (0) D3 (0) E3 (0.2)
A4 (0) B4 (0) C4 (0.1) D4 (0) E4 (0)
A5 (0) B5 (0) C5 (0) D5 (1.2) E5 (0)
A6 (0) B6 (0) C6 (0) D6 (0)
B7 (0) C7 (0) D7 (0)
B8 (0) C8 (0) D8 (0)
B9 (0)
Note. Females of various transgenic lineages (cex-L and cex-C) and
genetic backgrounds (B6 and BALB/c) were mated with nontransgenic
males. Pregnant B6-cex-L (mothers A to C), B6-cex-C (mother D), and
BALB/c-cex-L (mother E) females were sacrificed 1 day before delivery
and the HBeAg concentrations (in parentheses, expressed as ng/ml)
were determined in the sera of the mothers (A–E) and the respective
fetuses (A1-A6, B1-B9, C1-C8, D1-D8, E1-E5). Values from transgenic
animals are printed in bold type. Although the mothers expressed high
titers of HBeAg in their serum, the HBeAg could only be detected in the
sera of a few transgenic fetuses.
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of HBeAg, which might still be sufficient to induce toler-
ance, can be passed from the mother to the fetus. There-
fore, in the following experiments we directly analyzed
whether the nontransgenic offspring of HBeAg express-
ing transgenic mice show an impaired immune response
with respect to HBV core gene products.
HBcAg and HBeAg expressing plasmids are equally
well suited to inducing specific cytotoxic
immune responses
A major problem which severely hampered systematic
studies of the cytotoxic immune response directed
against HBV core gene products in the past was that it
was rather difficult to induce HBeAg- or HBcAg-specific
CTLs in mice. Recently we demonstrated that this prob-
lem can be overcome by immunization of mice with
plasmids which express the HBV core gene under the
control of the HCMV-IE promoter/enhancer. Using this
technique a very good core-specific cytotoxic immune
response could be elicited in H-2b mice which was
mainly directed against the peptide MGLKFRQL (HBcAg
amino acids 92–99) and restricted by the MHC class I
molecule Kb (Kuhrober et al., 1996).
To test whether core-specific CTLs could be induced
by not only the HBcAg but also the HBeAg, B6 mice were
immunized with three different plasmids expressing ei-
ther the wild-type or slightly modified variants of the HBV
preC/C gene. In plasmid pKH-29.1/30, the first nucleotide
of the preC ATG was deleted. Thus, this plasmid only
encodes the HBcAg. In plasmid pPP-E1 the core gene
ATG was converted into ATA. Consequently, only a
slightly modified HBeAg can be produced in which a
methionine is replaced by an isoleucine. Plasmid pGW-I1
contains the wild-type preC/C gene. However, since ex-
pression is regulated by the HCMV promoter/enhancer
only a single mRNA is transcribed, with the preC AUG
being the first AUG on this mRNA. As expected, upon
transfection of this plasmid into tissue culture cells only
HBeAg and its precursors could be detected (data not
shown). Ten to fourteen days after immunization, the
spleen cells were taken into culture and restimulated for
4 days with irradiated syngeneic stimulator cells, which
had been transfected with an HBcAg expression plasmid
(cell line RBL5/C). After restimulation, the HBcAg/HBeAg-
specific immune response was determined using recom-
binant RBL5/C cells and RBL5 controls as targets.
As is shown in Fig. 1, the CTL responses elicited by the
three different plasmids were nearly identical. Thus, in
spite of their different biosynthetic pathways the HBcAg
and the HBeAg are equally well suited to inducing a
cross-reacting cytotoxic immune response. For simplifi-
cation, only plasmid pGW-I1 was used for all further
immunizations.
DNA immunization fails to break CTL tolerance
in transgenic mice
DNA immunization is a relatively new technique which
is especially well suited to inducing CTL responses.
Since we wanted to test whether the HBeAg can induce
immunologic tolerance of cytotoxic T lymphocytes in
utero we had to exclude the possibility that such a
tolerance can be broken by DNA immunization.
FIG. 1. DNA immunization of B6 mice with core and e protein expressing plasmids elicits a specific cytotoxic T-cell response. B6 mice were
immunized with the core protein encoding plasmid pKH-29.1/30 (A), the e protein encoding plasmids pGW-I1 (B) and pPP-E1 (C), and the vector
plasmid pUC18 (D). Spleen cells were prepared from immunized mice 2 weeks postimmunization. The cells were restimulated with irradiated RBL5/C
transfectants and tested for H-2b-restricted cytolytic activity using HBcAg expressing recombinant RBL5/C target cells and RBL5 controls at the
indicated effector/target ratios. The data show representative chromium release assays performed with pooled splenocytes of two immunized
animals.
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To this end we evaluated the CTL response of cex-L mice
after immunization with plasmid pGW-I1. The results are
shown in Fig. 2. Syngeneic controls developed a normal
immune response, as demonstrated by the specific lysis of
the HBcAg expressing RBL5/C target cells (Figs. 2B and
2D), whereas no specific lysis was observed with the trans-
genic H-2b cex-L mice (Figs. 2A and 2C). This indicates that
B6-cex-L mice are tolerant at the CTL level and that this
tolerance is not broken by DNA immunization.
DNA immunization fails to induce seroconversion
in transgenic mice
Recently (Mancini et al., 1996), it has been described
that single genetic immunizations of transgenic mice
expressing the HBV surface proteins in their serum suf-
ficed to induce a vigorous synthesis of aHBs antibodies
which led to a seroconversion from HBsAg to aHBs.
Since in previous studies it has been shown that genetic
immunization with HBeAg encoding plasmids could in-
duce a significant humoral immune response against the
HBeAg in nontransgenic B6 mice (Kuhrober et al., 1996),
it was of interest to investigate whether DNA vaccination
would elicit aHBe antibodies in B6-cex transgenic mice.
Therefore, B6-cex-L and B6-cex-C mice as well as B6
controls were immunized with HBeAg expressing plas-
mid pGW-I1 and the HBeAg and a-HBeAg serum titers
were monitored. As is shown in Fig. 3E, the B6 control
mice developed a good HBeAg-specific humoral immune
response upon DNA immunization, whereas virtually no
HBeAg-specific antibodies could be detected in the sera
of the transgenic animals (Figs. 3C and 3D). Correspond-
ingly, the HBeAg serum titers of the immunized trans-
genic animals exhibited no significant changes during
the experiment (Figs. 3A and 3B). This shows that DNA
immunization fails to elicit HBeAg-specific antibodies in
cex transgenic mice of the haplotype H-2b.
This finding appears to be in contradiction to a previ-
ous report in which it was described that HBeAg ex-
pressing H-2b transgenic mice do not develop a com-
plete tolerance against this self-protein at the T-helper
and the B-cell levels (Milich et al., 1995). Although, as in
our mice, there was no spontaneous production of
a-HBe antibodies, a good HBeAg-specific humoral im-
mune response could be induced by immunization with a
peptide comprising amino acids 129–140 of the HBc/eAg
(p129–140). To test whether our mice showed the same
reactivity to this peptide, B6-cex-L and B6-cex-C mice
were immunized with peptide p129–140 and the HBeAg
and a-HBeAg serum titers were monitored. As shown in
Figs. 4C and 4D, a single injection of this peptide was
sufficient to induce a strong a-HBe response in both
transgenic lineages. The number of autoantibodies syn-
thesized was sufficient to induce a long-lasting serocon-
version from HBeAg to a-HBe (Figs. 4A and 4B). This
effect was not accompanied by elevated serum trans-
aminases or other signs of liver damage, indicating that
the a-HBe antibodies had no pathologic effect on HBeAg
expressing hepatocytes (data not shown).
Nontransgenic offspring of HBeAg expressing
transgenic mice show no HBc/eAg-specific CTL
immune tolerance
Since DNA immunization was not sufficient to break CTL
tolerance in our transgenic mice, this type of immunization
could be used to test whether nontransgenic offspring
which develop in HBeAg expressing mothers show an
impaired HBeAg-specific immune response in comparison
to normal controls. Transgenic B6-cex-L and B6-cex-C fe-
male mice were mated with nontransgenic C57BL/6J (B6) or
FIG. 2. DNA immunization cannot break CTL tolerance of H-2b cex-L
transgenic mice. Seven transgenic B6-cex-L (A) and 10 F1-cex-L (C)
mice as well as the same number of B6 (B) and F1 (D) controls were
immunized with HBeAg encoding plasmid pGW-I1 (F1 5 B6 3 BALB/c).
Spleen cells were prepared from immunized mice 2 weeks postimmu-
nization. The cells were restimulated with irradiated RBL5/C transfec-
tants and tested for H-2b-restricted cytolytic activity using HBcAg ex-
pressing recombinant RBL5/C target cells and RBL5 controls at the
indicated effector/target ratios.
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BALB/cJ males. After weaning the transgene genotype of
the offspring was analyzed by PCR and the mice were
immunized with plasmid pGW-I1. Since in previous studies
it had been demonstrated that tolerance of murine H-2s-
restricted HBc/eAg-specific Th cells induced by a single
HBcAg injection into newborn mice persisted up to the age
of 3 months (Milich et al., 1990), immunization was per-
formed at an age between 48 and 72 days. The vaccinated
animals were analyzed for HBc/eAg-specific CTL re-
sponses as described above. As is shown in Fig. 5, the
HBc/e-specific CTL response was comparable between
DNA-immunized mice which could have been exposed to
the HBeAg in utero (Figs. 5A and 5C) and syngeneic con-
trols (Figs. 5B and 5D). Thus, it appears that the HBeAg
either cannot induce tolerance in utero or that the amount
of HBeAg which can pass the placenta under normal cir-
cumstances is not sufficient to induce tolerance of H-2b-
restricted cytotoxic lymphocytes.
DISCUSSION
The question whether certain HBV gene products
can induce a virus-specific immune tolerance is an
issue of long standing. In particular, the secretory
variant of the capsid protein, the HBeAg, has been
suspected to facilitate the development or the main-
tenance of chronic infections for a long time. Two
different mechanisms of HBeAg-mediated immuno-
modulation have been proposed.
First, it was speculated that constitutive HBeAg ex-
pression is necessary for maintenance of chronic
courses of infection. This theory receives support from
immunological studies indicating that in the murine sys-
tem the secretory HBeAg preferentially induces immune
responses of a Th2 phenotype, whereas the particulate
HBcAg predominantly elicits Th1 reactions (Milich et al.,
1997). Since the Th1 and Th2 subsets are cross-regula-
tory (Hsieh et al., 1992; Seder et al., 1993) and the major
function of Th1 cells is the synthesis of proinflammatory
cytokines, circulating HBeAg might thus be essential to
avoid inflammatory exacerbations which could clear the
virus and/or kill the host. Clinical observations indicating
that the emergence of HBeAg-negative HBV mutants is
frequently associated with a deterioration of liver dis-
ease (Brunetto et al., 1991) may be attributed to this
HBeAg action.
On the other hand, it was proposed that the HBeAg
might enhance the efficiency of virus transmission. It is
well documented that chronically HBV-infected women
who are HBeAg positive transmit the virus much more
frequently to their babies than chronic HBV carriers who
are HBeAg negative (Okada et al., 1976). Since most
babies can be protected from infection if they are actively
and passively immunized immediately after birth (Beas-
ley et al., 1983; Lee et al., 1986), the placenta appears to
represent an efficient barrier for the virus and the major-
FIG. 3. DNA immunization fails to elicit HBeAg-specific antibodies in
B6-cex transgenic mice. Transgenic B6-cex-L (A, C) or B6-cex-C (B, D)
mice and B6 controls (E) were immunized with HBeAg encoding plasmid
pGW-I1 and the HBeAg (A, B) and aHBe (C, D, E) serum titers were
monitored 0, 4, and 8 weeks postimmunization. The data shown represent
mean values in Paul-Ehrlich-Units (PE-Units) a-HBe or ng HBeAg/ml se-
rum (plus standard deviation) of four determinations performed with the
sera of individual animals. Whereas the B6 mice showed a vigorous
HBeAg-specific humoral immune response upon DNA immunization (E),
virtually no HBeAg-specific antibodies could be detected in the sera of the
transgenic mice (C, D). Correspondingly the serum HBeAg expression of
the transgenic animals was not affected significantly (A, B). Comparable
results were obtained when 9 transgenic animals were immunized with
plasmid pGW-I1 twice or when 10 transgenic F1-cex animals were used
for the experiment (data not shown).
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ity of infections most likely occur during or shortly after
birth (Tong et al., 1981). Thus, it could be imagined that
the HBeAg can pass the placenta and induce some type
of immune tolerance in the fetus which later allows the
establishment of an infection with a high frequency
(Milich et al., 1990).
This hypothesis is attractive but suffers from the fact
that there are no data which unambiguously show that
the HBeAg can in fact be passed from the mother to the
fetus. In some studies umbilical cord sera were used for
HBeAg determination, which always bears the risk of
contamination with maternal blood (Arakawa et al., 1982;
Biswas et al., 1989). Another problem is that in none of
the studies could microleakage of maternal blood into
the circulation of the newborn during tearing of the pla-
centa at birth be safely excluded. Moreover, many of the
HBeAg-positive cases which have been reported were
obviously due to infections which already occurred in
utero (Lee et al., 1989; Li et al., 1986). In this context it is
also very important to stress that the virus titers of
HBeAg-positive carriers are usually several orders of
magnitudes higher as those of HBeAg-negative carriers.
This fact alone can explain the higher rate of virus
transmission.
FIG. 4. B6-cex transgenic mice are not tolerant at the level of T-helper
and B cells. Groups of six B6-cex-L and three B6-cex-C mice were
immunized with 100 mg of the HBc/eAg peptide p129–140, representing
an H-2b-restricted Th epitope. HBeAg (A, B) and aHBe (C, D) serum
titers were monitored at weeks 0, 3, 6, and 9 postimmunization. Auto-
reactive Th cells surviving in the periphery of B6-cex transgenic mice
could be activated by p129 - 140 peptide immunization. The resulting
vigorous aHBe antibody synthesis (C, D) was sufficient to virtually
completely neutralize circulating HBeAg in the serum (A, B).
FIG. 5. Nontransgenic mice born to HBeAg expressing mothers are
not tolerant at the level of H-2b-restricted core protein-specific CTLs.
Nontransgenic B6 or F1 (B6xBALB/c) mice born to HBeAg expressing
transgenic mothers of lineage cex-L (B6 born to cex-L, A; F1 born to
cex-L, C) and naive B6 (B) or F1 (D) controls were immunized with
HBeAg encoding plasmid pGW-I1. Spleen cells were prepared from
immunized mice 2 weeks postimmunization. The cells were restimu-
lated with irradiated RBL5/C transfectants and tested for cytolytic ac-
tivity using HBcAg expressing recombinant RBL5/C target cells and
RBL5 controls at the indicated effector/target ratios. The data show
representative chromium release assays performed with pooled
splenocytes of 3 (A, B) or 2 (C, D) genetically immunized animals each.
In total, 17 B6 or F1 mice, born to cex transgenic mothers, were DNA
immunized at an age of 48 to 72 days and the H-2b-restricted HBc/
eAg-specific CTL response was analyzed using individual or pooled
splenocytes. In all experiments we failed to detect signs of a reduced
cytotoxicity in comparison to naive syngenic controls.
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To our knowledge, there is only one study in which a
possible prenatal tolerogenic effect of the HBeAg was
experimentally tested (Milich et al., 1990). In this report it
was shown that H-2s splenocytes from nontransgenic
offspring of HBeAg expressing transgenic mice exhibit a
weaker lymphoproliferative response to HBV core gene
products compared to normal controls. The effect was
weak, yet significant, but no evidence was presented
that the HBeAg was in fact transferred from the mother to
the fetus. Since transgenic mice secrete the HBeAg at
least in urine (Guidotti et al., 1995), the observed effect
could also have resulted from the postnatal contact of
the newborn mice to excretions of their mothers. Further-
more, it has not been tested whether the lower prolifer-
ative response of the spleen cells had any effect on the
humoral or cellular immune response.
Here we have examined the question of whether a
possible exposure to the HBeAg in utero can result in an
impaired CTL immune response. We found no evidence
that the HBeAg can pass the placenta barrier. However,
since even minute amounts of antigen which could es-
cape detection with a serologic test might be sufficient to
induce tolerance, we analyzed the CTL immune re-
sponse of mice which developed in HBeAg-positive
mothers. To date, core-specific murine CTL responses
could be established successfully only by genetic immu-
nization of H-2b or H-2d mice (Kuhrober et al., 1996, 1997)
or by immunization of H-2k mice with retroviral vectors
(Townsend et al., 1997). Hence, it was not possible to
analyze the potential of HBeAg to induce CTL tolerance
in utero in H-2s mice which have been used in the
aforementioned study (Milich et al., 1990). The immune
reactions elicited by genetic immunization with HBc/eAg
encoding plasmids in H-2b mice were compared be-
tween nontransgenic animals potentially exposed to the
HBeAg in utero, HBeAg expressing transgenic mice, and
naive nontransgenic controls. In these experiments, effi-
cient HBc/eAg-specific H-2b-restricted CTL responses
could be elicited by immunizing naive nontransgenic
mice with HBeAg as well as with HBcAg encoding plas-
mids, which confirms previous reports showing that
these proteins are cross-reactive at the CTL level (Mis-
sale et al., 1993; Kuhrober et al., 1996; Townsend et al.,
1997). HBeAg expressing transgenic mice developed no
CTL response, showing that they were tolerant and that,
most importantly, this tolerance could not be broken by
genetic immunization. On the contrary, the nontransgenic
offspring of HBeAg-positive mothers revealed a normal
CTL response. This suggests that at least in H-2b mice
HBeAg cannot induce CTL tolerance in utero.
As has been described for H-2b transgenic mice ex-
pressing the HBeAg under the transcriptional regulation
of the metallothionein promoter (Milich et al., 1995), our
B6-cex transgenic mice were not tolerant at the Th/B-cell
level. Although there was no detectable spontaneous
production of a-HBeAg antibodies, such antibodies
could be induced by a single immunization with the
HBc/eAg peptide p129–140. Antibody production was
strong enough to result in a seroconversion from HBeAg
positive to a-HBeAg positive. Genetic immunization
failed to induce the same effect. This could be explained
by the lower amount of antigen expressed, the lack of
adjuvans, the different type of antigen presentation, or a
combination of these and other possibilities.
In summary, our experimental data do not support the
assumption that HBeAg can pass the placenta barrier. Of
course, it remains possible that an active transport
mechanism operates in humans which facilitates trans-
fer of HBeAg or that HBeAg complexed to a-HBe IgG
molecules can cross the placenta barrier (Arakawa et al.,
1982). We have furthermore shown that HBeAg poten-
tially passing the murine placenta in amounts undetect-
able by ELISA does not induce tolerance of H-2b-re-
stricted cytotoxic T cells. These data do not necessarily
challenge the findings of Milich et al. (1990), who re-
ported a tolerization of H-2s-restricted core protein-spe-
cific Th cells in nontransgenic mice born to HBeAg ex-
pressing mothers. This group studied a different kind of
T-cell response to a different immunogenic stimulus in a
different lineage of transgenic mice on a different MHC
haplotype. All of the latter parameters have the potential
to induce differences in the outcome of immunological
experiments. Possibly, low amounts of HBeAg which may
be transferred through the placenta of transgenic mice
may suffice to induce a weak tolerance of H-2s-restricted
Th cells, whereas CTLs of the haplotype H-2b are resis-
tant to this weak tolerogenic stimulus. Future studies will
have to address the issue of the potential of HBeAg to
induce tolerance in utero.
MATERIALS AND METHODS
Transgenic mice
All animals used in this study were maintained at the
Laboratory Animal Research Unit of the University of Ulm
under strict SPF conditions. The generation of the trans-
genic mouse lines cex-L and cex-C has been reported
(Reifenberg et al., 1997). Lineage B6-cex-L was gener-
ated by directly introducing the transgene into C57BL/6J
(5B6) mice. By backcrossing lineage B6-cex-L to the
BALB/c strain for seven generations we transferred the
cex-L transgene to the BALB/c background. The result-
ing congenic variant is referred to as BALB/c-cex-L. For
some experiments we also used BALB/cxB6-cex-L (5F1-
cex-L) transgenic hybrids. Lineage B6-cex-C was derived
from a transgenic (B6xCBA/Ca)F2 founder mouse and
backcrossed to the B6 strain for eight generations.
Transgenic mice were detected by PCR amplification of
transgene-specific sequences from chromosomal DNA
(primer combinations GGA GCT ACT GTG GAG TTA CTC
and ACA TTG AGA TTC CCG AGA TTG) or by detection of
serum HBeAg. Transgenic lineages cex-L and cex-C ex-
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press the HBV X and core genes under the transcrip-
tional regulation of the authentic hepadnaviral promoter
and enhancer sequences. High amounts of core protein
can be detected in liver, kidney, and pancreas. Moreover,
the sera are strongly HBeAg-positive. Transgenic ani-
mals were routinely bred by mating hemizygous trans-
genic males with nontransgenic females. Paternal inher-
itance of the transgene resulted in a good expression of
all core gene products in the offspring. In some experi-
ments hemizygous transgenic females were mated with
nontransgenic male mice. Maternal transmission of the
transgene led to a virtually complete suppression of core
gene expression.
Quantitative determination of HBeAg
HBeAg analyses were performed using the Abbott IMX
microparticle HBe assay system (Abbott Laboratories,
Wiesbaden, Germany). The test was quantitated with an
HBeAg reference antigen of the Paul-Ehrlich-Institut (Lan-
gen, Germany). By definition, this standard contains 100
Paul-Ehrlich Units HBeAg/ml. In parallel with each test
series a calibration curve was generated with serum sam-
ples containing 0, 2, or 5 Paul-Ehrlich Units (PEU) HBeAg/
ml. One PEU corresponds to about 1 ng of HBeAg (W. H.
Gerlich, personal communication). For simplification, we
present all HBeAg concentrations as ng/ml. To determine
the lower detection limit of the assay system we gradually
diluted the reference serum. As little as 0.1 ng HBeAg/ml
serum could be detected (data not shown).
Pregnant transgenic mice were killed by exposure to
CO2 at day 19 postconception. The fetuses were pre-
pared immediately and killed by decapitation. The blood
from the decapitation wound was collected and centri-
fuged and the serum stored at 220°C until use. At the
same time, blood was collected from the mother animals
by cardiac puncture. For quantitative determination of
HBeAg, 30 ml of murine serum was diluted with 120 ml
fetal calf serum and then subjected to the IMX HBe test.
Determination of serum antibody levels
HBeAg-specific antibodies were detected using the
IMX anti-HBe assay (Abbott). The test was standardized
using a reference serum of the Paul-Ehrlich-Institut.
Generation of core and e protein encoding plasmids
for DNA immunization
All nucleotide positions are relative to the core gene
ATG with the A being nucleotide 1. Three different ex-
pression plasmids were constructed. To generate a con-
struct which encodes only the core protein, plasmid
pMH3/3097, which contains an HBV overlength genome
(Junker et al., 1987), was digested with BamHI and reli-
gated. The resulting plasmid contained the HBV ayw
sequences from nucleotide positions 3097 to 1004 (core
gene) and 2682 to 84 (genome fragment including the
hepadnaviral polyadenylation signal). The metallothio-
nein promoter of plasmid pMH3/3097 was excised by
digestion with PstI and HindIII and replaced by the im-
mediate early promoter/enhancer of the human cytomeg-
alovirus (HCMV-IE). The resulting plasmid pKH-29.1/30
contains only the second ATG of the preC/C gene and
therefore codes only for the core protein.
Preparation of plasmid pGW-I1 was done in the same
way, with only the exception that the construction started
with plasmid pMH3/3091 (Junker et al., 1987). This construct
contains the wild-type preC sequence with both the pre-
core and the core ATG. However, since transcription is
controlled by the HCMV promoter/enhancer only a single
mRNA is produced, with the precore AUG being the first
AUG on this message. The only core gene products which
could be detected after transfection of this plasmid into
tissue culture cells as well as in transgenic mice express-
ing this construct were the HBeAg and its precursors.
Although we never observed any HBcAg after expres-
sion of plasmid pGW-I1, we constructed a third plasmid,
referred to as pPP-E1, in which the core ATG was con-
verted into an ATA by site-directed mutagenesis. Conse-
quently, only the HBeAg and its precursors can be ex-
pressed from this plasmid.
DNA and peptide immunization
The DNA used for immunizations was isolated from
transformed Escherichia coli cultures using the Qiagen
plasmid extraction kit (Qiagen, Hilden, Germany). DNA
immunizations were performed with plasmid pKH-29.1/
30, pGW-I1, or pPP-E1 by injecting 50 ml plasmid solution
(1 mg/ml) into the regenerating musculus tibialis anterior
5 days after pretreatment with cardiotoxin (Latoxan, Ro-
sans, France; Davis et al., 1993a,b).
Peptide p129–140 (PPAYRPPNAPIL) was synthesized
in an Applied Biosystems peptide synthesizer Model
431A (Foster City, CA) and purified by reverse-phase
HPLC. For subcutaneous immunizations at the base of
the tail the peptide was dissolved in destilled water and
emulsified with adjuvant.
Cytotoxicity assay
Spleen cells from immunized mice were cultured in
a-MEM supplemented with 10 mM HEPES, 5 3 1025 M
2-mercaptoethanol, antibiotics, and 10% v/v fetal calf
serum. For restimulation, the syngeneic core protein ex-
pressing recombinant cell line RBL5/C was used (Kuh-
rober et al., 1996). Responder cells (3 3 107) were cocul-
tured with 1.5 3 106 irradiated (20,000 rad) stimulator
cells in 10 ml medium in upright 25-cm2 tissue culture
flasks in a humidified atmosphere (7% CO2) at 37°C.
Cytotoxic effector populations were harvested after day 4
of cocultivation and washed twice. Serial dilutions of
effector cells were incubated with 2 3 103 51Cr-labeled
RBL5/C target cells in round-bottom microtiter plates for
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4 h. The percentage specific lysis was calculated as
[(experimental release - spontaneous release) / (total
release - spontaneous release)] 3 100. The spontane-
ously released 51Cr was always less than 20% of the total
label. Data shown are the mean values of triplicate
determinations.
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